TAG:
commercial laboratories
Aureon Biosciences, Bayer, Competitive Technologies, Rare Blood Infections, Kaiser Permanente
By Robert Michel | From the Volume XI No. 16 – November 22, 2004 Issue
KEVIN JOHNSON AND VIJAY AGGARWAL JOIN AUREON BIOSCIENCES TWO VETERAN LAB EXECUTIVES are back in the business. Kevin Johnson is now the Chairman at Aureon Biosciences Corporation and Vijay Aggarwal, Ph.D. is President and CEO. The fact that both men chose to join Aureon Bios…
How Local Path Groups Can Keep Patient Access
By Robert Michel | From the Volume XI No.13 – September 20, 2004 Issue
CEO SUMMARY: For pathology groups operating their own histology and cytology labs, a growing problem is access to patients covered by exclusive managed care contracts. In the Northeast, several persistent pathology group practices are using some effective business strategies to fight this…
Lab Contracting Fracas In British Columbia
By Robert Michel | From the Volume XI No. 6 – April 26, 2004 Issue
CEO SUMMARY: Government healthcare officials in British Columbia are taking definitive steps to recast the existing status quo between private commercial laboratory companies and public (government) hospital laboratories in the province. Although the stated goals are to reduce the cost of…
Seattle Hospital Lab JVs Involve Quest & LabCorp
By Robert Michel | From the Volume XI No. 5 – April 5, 2004 Issue
CEO SUMMARY: Joint ventures and collaborative business relationships between hospital laboratories and commercial laboratories continue to be a difficult business model. Recent events in Seattle demonstrate the challenges and frustrations of establishing such ventures, then making them su…
LabCorp Buys MDS Labs In New York and Georgia
By Robert Michel | From the Volume XI No. 5 – April 5, 2004 Issue
CEO SUMMARY: It’s the final chapter of the “Canadian Invasion” of the U.S. laboratory testing market. In the mid-1990s, both MDS and Dynacare built a sizeable presence in the United States as they both worked to develop joint ventures with hospital laboratories. Dynacare was acquire…
Diversifying Lab Management’s “Gene Pool” of Methods
By R. Lewis Dark | From the Volume XI No. 3 – February 23, 2004 Issue
I ENCOURAGE OUR CLIENTS AND REGULAR READERS to give careful thought to the intelligence findings provided by our editor about the unfolding laboratory joint venture in Cincinnati between LabOne, Inc. and The Health Alliance. (See …
LabOne in Cincinnati: Watch Events Unfold
By Robert Michel | From the Volume XI No. 3 – February 23, 2004 Issue
CEO SUMMARY: It’s another example of a commercial laboratory taking over the laboratory assets of a multi-hospital consolidated laboratory. Will LabOne manage these assets and get more growth, more cost savings, and more profit? If this happens, it will mark the third time in r…
Anatomic Path Trends Portend Deep Changes
By Robert Michel | From the Volume XI No. 1 – January 12, 2004 Issue
CEO SUMMARY: Our biannual review of trends shaping the anatomic pathology profession reveals that a wide range of influences are active. The nation’s healthcare system is undergoing fundamental changes in how it views the quality of health services and how it will favor top-performing p…
2003’s Big Lab Stories Reflect Health Trends
By Robert Michel | From the Volume X No. 17 – December 22, 2003 Issue
CEO SUMMARY: At a minimum, 2003 proved to be a year of relative stability for the laboratory industry, as demonstrated by THE DARK REPORT’S “Ten Biggest Lab Stories of 2003.” The year was free of industry-wide crises and scan- dals. That allowed most laboratory administrators and pa…
Who’s Buying Labs? Activity Shifts Down
By Robert Michel | From the Volume X No. 17 – December 22, 2003 Issue
CEO SUMMARY: As the number of independent clinical laboratories dwindles, most remaining owners seem content to continue building their business—at least until a buyer makes them an offer “they can’t refuse.” Acquisitions of pathology group practices were also few in number during…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized